TrialAnnals of hematology2023

Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects.

Inge G P Geelen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.